Powder: -20°C for 3 years | In solvent: -80°C for 1 year
KS370G (Caffeic Acid Phenethyl Amide) 抑制 UUO 诱导的肾纤维化标志物表达。KS370G 是一种具有口服活性的降糖和心血管保护剂,可减少梗阻肾脏中胶原蛋白的沉积,并显著降低肾脏炎症趋化因子/粘附分子和单核细胞标志物的表达,改善压力过载小鼠心脏左室肥厚和功能。KS370G 可用于研究肾阻塞性肾病。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 483 | 现货 | ||
5 mg | ¥ 1,100 | 现货 | ||
10 mg | ¥ 1,630 | 现货 | ||
25 mg | ¥ 2,800 | 现货 | ||
50 mg | ¥ 4,160 | 现货 | ||
100 mg | ¥ 5,930 | 现货 | ||
500 mg | ¥ 12,200 | 现货 |
产品描述 | KS370G (Caffeic Acid Phenethyl Amide) inhibits UUO-induced renal fibrosis marker expression. KS370G is an orally active hypoglycemic and cardioprotective agent that reduces collagen deposition in obstructed kidneys and significantly decreases renal expression of inflammatory chemokines/adhesion molecules and monocyte markers and improves left ventricular hypertrophy and function in the heart of pressure-overloaded mice.KS370G can be used to study renal obstructive nephropathy. |
靶点活性 | NO:0.44 μM(EC50) |
体外活性 | KS370G (0.35、1.05、1.75、3.5 uM) significantly inhibited the release of nitric oxide (NO) and the expressions of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2). Treatment with KS370G also induced heme oxygenase (HO)-1 and suppressors of cytokine signaling (SOCS)-3 expression in the microglia. Furthermore, the anti-inflammatory effects of KS370G were found to be regulated by phosphorylated adenosine monophosphate-activated protein kinase-α (AMPK-α) translocated to the nucleus. Moreover, KS370G showed significant anti-neuroinflammatory effects on microglial activation in vivo and on motor behavior as well.[3] |
体内活性 | KS370G 1mg/kg (1mg/kg; chronic oral gavage; once a day) inhibited cardiac hypertrophy and improved cardiac function induced by pressure overload. KS370G also decreased the plasma levels of atrial natriuretic peptide and lactate dehydrogenase. Besides, pressure overload-induced increases of α-SMA and phosphorylation of ERK, AKT, and GSK3β were significantly reduced by chronic oral treatment with KS370G. We also found that chronic oral treatment with KS370G reduced cardiac collagen accumulation. KS370G improved left ventricular function and inhibited cardiac hypertrophy through the decrease of the phosphorylation of ERK, AKT, and GSK3β in pressure-overload mice hearts.[4] |
别名 | KS-370-G, KS 370 G, Caffeic Acid Phenethyl Amide |
分子量 | 283.32 |
分子式 | C17H17NO3 |
CAS No. | 105955-01-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 45 mg/mL (158.83 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 3.5296 mL | 17.6479 mL | 35.2958 mL | 88.2394 mL |
5 mM | 0.7059 mL | 3.5296 mL | 7.0592 mL | 17.6479 mL | |
10 mM | 0.353 mL | 1.7648 mL | 3.5296 mL | 8.8239 mL | |
20 mM | 0.1765 mL | 0.8824 mL | 1.7648 mL | 4.412 mL | |
50 mM | 0.0706 mL | 0.353 mL | 0.7059 mL | 1.7648 mL | |
100 mM | 0.0353 mL | 0.1765 mL | 0.353 mL | 0.8824 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
KS370G 105955-01-9 KS-370-G KS 370 G Caffeic Acid Phenethyl Amide Inhibitor inhibitor inhibit